**Burden Statement:** Burden in this context means the time expended by persons to generate, maintain, retain, disclose, or provide the information requested. This includes the time needed to review instructions, to develop, acquire, install and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information, to train personnel and to be able to respond to a collection of information, to search data sources, to complete and review the collection of information, and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below.

### TOTAL ESTIMATED ANNUALIZED BURDEN-HOURS

<table>
<thead>
<tr>
<th>Form name</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden per response (in hours)</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family Planning Annual Report: Forms and Instructions</td>
<td>93</td>
<td>1</td>
<td>36</td>
<td>3,348</td>
</tr>
<tr>
<td>Total</td>
<td>93</td>
<td>1</td>
<td>36</td>
<td>3,348</td>
</tr>
</tbody>
</table>

OS specifically requests comments on (1) The necessity and utility of the proposed information collection for the proper performance of the agency’s functions, (2) the accuracy of the estimated burden, (3) ways to enhance the quality, utility, and clarity of the information to be collected, and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Keith A. Tucker,  
Information Collection Clearance Officer.  
[FR Doc. 2013–11949 Filed 5–17–13; 8:45 am]

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

Centers for Disease Control and Prevention

**Informational Meeting Concerning Compliance With the Centers for Disease Control and Prevention’s Import Permit Program; Public Webcast**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).  
**ACTION:** Notice of public webcast.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS) announces a public webcast that will address the new import permit regulations for infectious biological agents, standards, and vectors; import permit inspections; and import permit exemptions. The purpose of this notice is to inform all interested parties, including those individuals and entities already possessing an import permit of the webcast.

**DATES:** The webcast will be held on Friday, July 12, 2013 from 1 p.m. to 5 p.m. EST. Those wishing to join the webcast are encouraged to register by July 5, 2013. Registration instructions are found on the HHS/CDC’s Import Permit Program Web site, http://www.cdc.gov/od/eaipp/index.htm.

**ADDRESSES:** The webcast will be broadcast from the Centers for Disease Control and Prevention, 1600 Clifton Road NE., Atlanta, Georgia 30329.

**FOR FURTHER INFORMATION CONTACT:** Von McClee, Division of Select Agents and Toxins, Office of Public Health Preparedness and Response, Centers for Disease Control and Prevention, 1600 Clifton Road NE., MS A–46, Atlanta, GA 30333; phone: 404–718–2000; email: lrsat@cdc.gov.

**SUPPLEMENTARY INFORMATION:** On February 4, 2013, the Centers for Disease Control and Prevention (CDC) in the Department of Health and Human Services (HHS) published a final rule (78 FR 7674) amending etiological importation regulations to (1) clarify import permit regulatory definitions, (2) increase oversight by implementing inspections, (3) address exemptions and (4) describe the appeal process.

This webcast is an opportunity for the regulated community (i.e., academic institutions and biomedical centers, commercial manufacturing facilities, federal, state, and local laboratories, including clinical and diagnostic laboratories, research facilities, exhibition facilities, and educational facilities) and other interested individuals to obtain specific regulatory guidance and information regarding the newly amended regulations. The webcast will also provide assistance to those interested in applying for an etiological import permit. Representatives from HHS/CDC will be present during the webcast to address questions and concerns from the web participants.

Topics to be discussed during the webcast include: The new import permit regulations for infectious biological agents, standards, and vectors; import permit inspections; and import permit exemptions. A question and answer session will take place after each topic.

Individuals wishing to join the webcast are encouraged to register by July 5, 2013. Instructions for registration are found on the HHS/CDC’s Import Permit Program Web site, http://www.cdc.gov/od/eaipp/index.htm. This is a webcast only event and there will be no on-site participation at the HHS/CDC broadcast facility. In-person participation cannot be accommodated. Closed-captioning video of the webcast will be available at http://www.cdc.gov/od/eaipp/index.htm after the webcast.

Dated: May 14, 2013.

Tanja Popovic,  
Deputy Associate Director for Science, Centers for Disease Control and Prevention.  
[FR Doc. 2013–11895 Filed 5–17–13; 8:45 am]

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Pediatrics Subcommittee.
Date: June 13, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Rita Anand, Ph.D., Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, 301–496–1487, anandr@mail.nih.gov.

Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Obstetrics and Maternal-Fetal Biology Subcommittee.
Date: June 26, 2013.
Time: 8:30 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Doubletree Hotel Bethesda (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Peter Zelazowski, Ph.D., Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, 301–435–6902, peter.zelazowski@nih.gov.

Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Obstetrics and Maternal-Fetal Biology Subcommittee.
Date: June 13–14, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Residence Inn Bethesda, Calvert I and II, 7335 Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Carla T. Walls, Ph.D., Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Boulevard, Room 5B01, Bethesda, MD 20892, 301–435–6898, wallsa@mail.nih.gov.

Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Population Sciences Subcommittee.
Date: June 27, 2013.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Renaissance Mayflower Hotel, 1127 Connecticut Avenue NW., Washington, DC 20036.
Contact Person: Marita R. Hopmann, Ph.D., Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health And Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, 301–435–6911, hopmannm@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)
Dated: May 14, 2013.

Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013–11859 Filed 5–17–13; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Recombinant DNA Advisory Committee.
Date: June 11–12, 2013.
Time: June 11, 2013, 8:00 a.m. to 5:30 p.m.
Agenda: The NIH Recombinant DNA Advisory Committee (RAC) will review and discuss selected human gene transfer protocols and related data management activities. The detailed, Draft agenda for the meeting is available on the OBA Web site, RAC Meeting page at this URL: http://oba.od.nih.gov/rdna/rac/rac_meetings.html.
Place: National Institutes of Health, Building 31C, 6th Floor, Conference Room 6, 9000 Rockville Pike, Bethesda, MD 20892.

Name of Committee: Recombinant DNA Advisory Committee.
Date: June 13, 2013.
Time: 8:00 a.m. to 3:15 p.m.
Agenda: The NIH Recombinant DNA Advisory Committee (RAC) will review and discuss selected human gene transfer protocols and related data management activities. The detailed, Draft agenda for the meeting is available on the OBA Web site, RAC Meeting page at this URL: http://oba.od.nih.gov/rdna/rac/rac_meetings.html.
Place: National Institutes of Health, Building 31C, 6th Floor, Conference Room 6, 9000 Rockville Pike, Bethesda, MD 20892.

Contact Person: Chezelle George, Office of Biotechnology Activities, Office of Science Policy/OD, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892, 301–496–9838, georgec@od.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.
In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit.
Information is also available on the Institute’s/Center’s home page: http://oba.od.nih.gov/rdna/ rdna.html, where an agenda and any additional information for the meeting will be posted when available.
OMB’s “Mandatory Information Requirements for Federal Assistance Program Announcements” (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these.